This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tack, K. J. Articles by Hedrick, J. A. Search for Related Content PubMed PubMed Citation Articles by Tack, K. J. Articles by Hedrick, J. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, 04 1997, 739-742, Vol 41, No. 4
Copyright © 1997 by the American Society for Microbiology. All rights reserved.

Study of use of cefdinir versus cephalexin for treatment of skin infections in pediatric patients. The Cefdinir Pediatric Skin Infection Study Group

KJ Tack, CH Keyserling, J McCarty and JA Hedrick
Parke-Davis Pharmaceutical Research, Ann Arbor, Michigan 48105, USA. tackk@aa.wl.com

Three hundred ninety-four patients, aged 6 months to 12 years, entered a multicenter, randomized, controlled, investigator-blind study comparing cefdinir, 7 mg/kg of body weight twice a day, with cephalexin, 10 mg/kg four times a day, each given for 10 days. The most common infections treated were impetigo and secondary infection of preexisting dermatitis. The most common pathogens isolated were Staphylococcus aureus and Streptococcus pyogenes. Two hundred thirty- one patients were microbiologically evaluable. Microbiologic eradication rates were 164 of 165 pathogens (99.4%) in the cefdinir group and 152 of 156 pathogens (97.4%) in the cephalexin group (P = 0.14). Clinical cure rates were 116 of 118 patients (98.3%) in the cefdinir group and 106 of 113 patients (93.8%) in the cephalexin group (P = 0.056). Sixteen percent of cefdinir patients and 11% of cephalexin patients experienced adverse events (P = 0.11), the most common being diarrhea, which affected 8% of the cefdinir group and 4% of the cephalexin group. Cefdinir appears to be an effective and well- tolerated agent for the treatment of uncomplicated skin and skin structure infections in pediatric patients.

This article has been cited by other articles:

• Jones, R. N., Nilius, A. M., Akinlade, B. K., Deshpande, L. M., Notario, G. F. (2007). Molecular Characterization of Staphylococcus aureus Isolates from a 2005 Clinical Trial of Uncomplicated Skin and Skin Structure Infections. Antimicrob. Agents Chemother. 51: 3381-3384 [Abstract] [Full Text]  
• Block, S L (2006). Searching for the Holy Grail of acute otitis media.. Arch. Dis. Child. 91: 959-961 [Full Text]  
• Block, S. L. (2006). Comparative Tolerability, Safety and Efficacy of Tablet Formulations of Twice-Daily Clarithromycin 250 mg versus Once-Daily Extended-Release Clarithromycin 500 mg in Pediatric and Adolescent Patients. CLIN PEDIATR 45: 641-648 [Abstract]